Last reviewed · How we verify
exenatide (Byetta)
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | exenatide (Byetta) |
|---|---|
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, an incretin hormone. It binds to GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing glucagon secretion. These combined effects lower blood glucose levels in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Headache
- Injection site reactions
Key clinical trials
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- Exenatide For Reducing the Reinforcing Effects of Cocaine (PHASE1)
- GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (PHASE2)
- Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome (PHASE3)
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) (PHASE4)
- A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: